Omnicell (NASDAQ:OMCL) Posts Earnings Results, Beats Expectations By $0.22 EPS

Omnicell (NASDAQ:OMCL) issued its quarterly earnings data on Tuesday. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22, FiscalAI reports. The business had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.01 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The firm’s quarterly revenue was up 14.9% on a year-over-year basis. During the same period last year, the business posted $0.26 earnings per share. Omnicell updated its FY 2026 guidance to 1.800-2.000 EPS and its Q2 2026 guidance to 0.400-48.000 EPS.

Here are the key takeaways from Omnicell’s conference call:

• Omnicell beat Q1 guidance with $310M revenue, $45M non‑GAAP EBITDA and $0.55 non‑GAAP EPS, and raised full‑year non‑GAAP EBITDA and EPS guidance to $153M–$168M and $1.80–$2.00, respectively.
• The company launched the next‑generation Titan XT and cloud platform OmniSphere; initial Titan hardware shipments are planned for H2 2026 with OmniSphere functionality phased in starting H1 2027, representing a multi‑year replacement opportunity (> $2.5B total) despite multi‑quarter capital approval cycles.
• Recurring‑revenue momentum underpins visibility—Q1 product revenue grew 20% YoY, service revenue grew 8% YoY, and year‑end ARR is targeted at $680M–$700M, with management emphasizing more linear revenue pacing through 2026.
• Management reports a strong competitive pipeline and increasing conversion opportunities as customers reassess incumbents (cited wins/expansions with the VA, academic medical center and specialty pharmacies), which management expects to contribute to future bookings.
• Near‑term headwinds include lower cash ($239M) mainly from debt repayment and prior buybacks, an estimated $12M of tariff‑related costs in 2026, and potential margin/expense variability as some spending is shifted into Q2–Q3.

Omnicell Stock Down 1.6%

Shares of Omnicell stock traded down $0.73 during trading hours on Wednesday, reaching $44.78. 124,430 shares of the company’s stock were exchanged, compared to its average volume of 615,853. The stock has a market cap of $2.04 billion, a P/E ratio of 1,119.78, a P/E/G ratio of 1.35 and a beta of 0.85. The company has a 50 day moving average of $37.02 and a two-hundred day moving average of $39.40. The company has a current ratio of 1.43, a quick ratio of 1.22 and a debt-to-equity ratio of 0.14. Omnicell has a fifty-two week low of $22.66 and a fifty-two week high of $55.00.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Piper Sandler reissued an “overweight” rating and issued a $49.00 price target (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Zacks Research upgraded Omnicell from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Bank of America raised Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price on the stock in a research report on Wednesday, February 4th. Benchmark restated a “buy” rating on shares of Omnicell in a research note on Friday, March 13th. Finally, Wells Fargo & Company upped their price target on Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $60.67.

Key Headlines Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Q1 results beat consensus — EPS $0.55 vs $0.33 est and revenue $309.9M (up 14.9% y/y); Omnicell said revenue and profitability improved, driving the rally. Omnicell Announces First Quarter 2026 Financial Results
• Positive Sentiment: Raised guidance — FY‑2026 EPS range 1.80–2.00 and Q2 outlook above consensus, signaling confidence in continued margin expansion and revenue cadence. Q1 Slide Deck / Press Materials
• Positive Sentiment: Analyst support — Bank of America’s Allen Lutz reiterated a Buy and maintained a $70 price target, reinforcing investor confidence in the company’s multi‑year product cycle and margin outlook. Analyst Reiterates Buy on Omnicell
• Positive Sentiment: Management hire — Omnicell named Rick Couldry SVP, Chief Pharmacy & Clinical Officer, a move that may bolster commercial execution and customer credibility in hospital pharmacy markets. Omnicell Welcomes Rick Couldry
• Neutral Sentiment: Market coverage and analysis — Multiple outlets published earnings recaps and the full earnings transcript/slide deck; useful for drilling into segment performance and management commentary. Earnings Transcript / Coverage
• Negative Sentiment: Valuation and profitability caveats — despite the beat, trailing net margin remains slim and reported P/E is extremely elevated, leaving shares sensitive to any execution or margin setbacks. (Refer to company financials and analyst notes above.)

Insider Activity

In related news, EVP Corey J. Manley sold 7,405 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $34.69, for a total transaction of $256,879.45. Following the sale, the executive vice president owned 96,717 shares in the company, valued at approximately $3,355,112.73. This represents a 7.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.92% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Several large investors have recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new position in shares of Omnicell in the second quarter valued at $26,000. Kemnay Advisory Services Inc. acquired a new stake in Omnicell in the fourth quarter valued at $58,000. Parkside Financial Bank & Trust grew its position in shares of Omnicell by 1,708.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after acquiring an additional 1,264 shares during the period. Van ECK Associates Corp increased its stake in shares of Omnicell by 75.1% during the 4th quarter. Van ECK Associates Corp now owns 2,294 shares of the company’s stock worth $104,000 after purchasing an additional 984 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Omnicell by 385.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock worth $146,000 after purchasing an additional 3,932 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.